Roche: New Phase 3 analyses show that a single dose of REGEN-COV (casirivimab and imdevimab) provides long-term protection against COVID-19 Montag, 08. November 2021 - 13:19

Investor Update

New Phase 3 analyses show that a single dose of REGEN-COV (casirivimab and imdevimab) provides long-term protection against COVID-19

Dear Investor,

Please find attached a press release from our partner Regeneron regarding new follow-up analyses of the 2069 prevention trial that add to the increasing body of evidence supporting the use of Ronapreve to prevent COVID-19:

https://investor.regeneron.com/news-releases/news-release-details/new-phase-3-analyses-show-single-dose-regen-covr-casirivimab-and

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com	Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com	Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com